Alex Leech
Private Equity Investor bei BiovelocITA Srl
Profil
Alex Leech is currently a Partner at Sofinnova Partners SAS and BiovelocITA Srl.
Previously, he was the Chief Executive Officer & Director at Creabilis Therapeutics Srl, Alchemab Therapeutics Ltd., and Creabilis Holdings Ltd.
He also held positions as Principal at Ford Motor Co., Head-European Project Management at Pfizer Inc., Venture Partner at SV Health Investors LLP, and Head-Operations at Solace Pharmaceuticals, Inc. Leech received an undergraduate degree from the University of Sussex and an MBA from Henley Management College.
Aktive Positionen von Alex Leech
Unternehmen | Position | Beginn |
---|---|---|
BiovelocITA Srl
BiovelocITA Srl Investment ManagersFinance Biovelocita Srl (Biovelocita) is a venture capital firm founded in 2015 by Silvano Spinelli, Gabriella Camboni and Sofinnova Partners. The firm is headquartered in Milan, Italy. | Private Equity Investor | 13.12.2023 |
Sofinnova Partners SAS
Sofinnova Partners SAS Investment ManagersFinance Sofinnova Partners SA (Sofinnova) is an independent venture capital firm established in 1972 and headquartered in Paris, France. Originally known as Sofinnova, the first venture capital firm created in France, the firm created a U.S. subsidiary in San Francisco in 1976. In 1997, both firms were bought out by their management teams, which become the majority shareholders of the new companies, Sofinnova Partners in Paris and Sofinnova Ventures in San Francisco. | Private Equity Investor | 01.09.2023 |
Ehemalige bekannte Positionen von Alex Leech
Unternehmen | Position | Ende |
---|---|---|
Alchemab Therapeutics Ltd.
Alchemab Therapeutics Ltd. BiotechnologyHealth Technology Alchemab Therapeutics Ltd. engages in developing of antibodies. It focuses on discovering and developing novel therapeutics for patients. The company was founded in 2019 and is headquartered in Kings Cross, the Unite Kingdom. | Vorstandsvorsitzender | 22.06.2021 |
Creabilis Holdings Ltd.
Creabilis Holdings Ltd. Pharmaceuticals: MajorHealth Technology Creabilis Holdings Ltd. operates as a biotechnology company. The company was founded on June 7, 2013 and is headquartered in Canterbury, the United Kingdom. | Vorstandsvorsitzender | 06.12.2016 |
Solace Pharmaceuticals, Inc.
Solace Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Solace Pharmaceuticals, Inc. develops therapies for the treatment of neuropathic pain. It offers therapies for neuropathic and inflammatory pain. It offers discovery and development of innovative therapies for pain through in-house drug discovery and development programs as well as through selected partnerships. The company was founded in March 2006 by Allan Basbaum, Bruce Bean, Joyce Deleo and Tony Yaksh and is headquartered in Boston, MA. | Geschäftsführer | 04.08.2011 |
SV Health Investors LLP
SV Health Investors LLP Investment ManagersFinance SV Health Investors LLP (SV Health Investors) is a venture capital firm founded in 1994 by Peter McPartland. The firm is headquartered in London. | Private Equity Investor | - |
FORD MOTOR COMPANY | Corporate Officer/Principal | - |
Ausbildung von Alex Leech
University of Sussex | Undergraduate Degree |
Henley Management College | Masters Business Admin |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Börsennotierte Unternehmen | 2 |
---|---|
PFIZER, INC. | Health Technology |
FORD MOTOR COMPANY | Consumer Durables |
Private Unternehmen | 7 |
---|---|
Solace Pharmaceuticals, Inc.
Solace Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Solace Pharmaceuticals, Inc. develops therapies for the treatment of neuropathic pain. It offers therapies for neuropathic and inflammatory pain. It offers discovery and development of innovative therapies for pain through in-house drug discovery and development programs as well as through selected partnerships. The company was founded in March 2006 by Allan Basbaum, Bruce Bean, Joyce Deleo and Tony Yaksh and is headquartered in Boston, MA. | Health Technology |
Creabilis Therapeutics Srl
Creabilis Therapeutics Srl Pharmaceuticals: MajorHealth Technology Creabilis Therapeutics SRL discovers, develops, and markets prescription medicines to treat skin disease. Its products include CT200 and CT335, which is used to treat Behcet's disease; and CT327, which is used for the treatment of psoriasis, atopic dermatitis, and overgrowth of keratinocytes. The company’s products also include CT400, which is used for developing inhibitors of HGMB-1; and CT500 for the treatment of inflammatory disorders. The company was founded by Alfredo Boni in 2003 and is headquartered in Colleretto Giacosa, Italy. | Health Technology |
Creabilis Holdings Ltd.
Creabilis Holdings Ltd. Pharmaceuticals: MajorHealth Technology Creabilis Holdings Ltd. operates as a biotechnology company. The company was founded on June 7, 2013 and is headquartered in Canterbury, the United Kingdom. | Health Technology |
SV Health Investors LLP
SV Health Investors LLP Investment ManagersFinance SV Health Investors LLP (SV Health Investors) is a venture capital firm founded in 1994 by Peter McPartland. The firm is headquartered in London. | Finance |
Alchemab Therapeutics Ltd.
Alchemab Therapeutics Ltd. BiotechnologyHealth Technology Alchemab Therapeutics Ltd. engages in developing of antibodies. It focuses on discovering and developing novel therapeutics for patients. The company was founded in 2019 and is headquartered in Kings Cross, the Unite Kingdom. | Health Technology |
BiovelocITA Srl
BiovelocITA Srl Investment ManagersFinance Biovelocita Srl (Biovelocita) is a venture capital firm founded in 2015 by Silvano Spinelli, Gabriella Camboni and Sofinnova Partners. The firm is headquartered in Milan, Italy. | Finance |
Sofinnova Partners SAS
Sofinnova Partners SAS Investment ManagersFinance Sofinnova Partners SA (Sofinnova) is an independent venture capital firm established in 1972 and headquartered in Paris, France. Originally known as Sofinnova, the first venture capital firm created in France, the firm created a U.S. subsidiary in San Francisco in 1976. In 1997, both firms were bought out by their management teams, which become the majority shareholders of the new companies, Sofinnova Partners in Paris and Sofinnova Ventures in San Francisco. | Finance |